Drugs A-Z

Drugs

All Drugs Drugs A-Z Drug Classes (ATC) Drug Targets Structure Gallery

Categories

Therapeutic Areas Side Effects

Featured

ENCYCLOPEDIA

4,000+ Drug Profiles

Molecular data, mechanisms, and clinical pharmacology.

Guide Series

All Guides Glossary Tools

Explore

Timeline

Reference Content

Comparisons

Head-to-head drug analyses

Drug Journeys

ADME narratives

Drug Families

SAR structural relationships

Tools

View all results

No results found

🇺🇸 English

💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides

All Drugs Drug Classes Therapeutic Areas Side Effects

Guides Glossary Timeline

Comparisons Drug Journeys Drug Families

🇺🇸 English

Same Indication

Durvalumab vs Zanidatamab

Durvalumab vs Zanidatamab: Overview

This comparison examines the pharmacological differences between Durvalumab and Zanidatamab.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Pharmacokinetics

Half-life: Durvalumab — 17 days.

Chemical Properties

Type: Durvalumab — Antibody; Zanidatamab — Antibody.